Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Down 27.2% in July

Posted by MarketBeat News on Aug 2nd, 2022

Athira Pharma, Inc. (NASDAQ:ATHA – Get Rating) saw a large decrease in short interest in July. As of July 15th, there was short interest totalling 2,030,000 shares, a decrease of 27.2% from the June 30th total of 2,790,000 shares. Approximately 5.9% of the company’s shares are short sold. Based on an average daily volume of 941,600 shares, the short-interest ratio is currently 2.2 days.

Athira Pharma Trading Down 4.0 %

Shares of Athira Pharma stock opened at $3.34 on Tuesday. Athira Pharma has a 1 year low of $2.53 and a 1 year high of $16.65. The company has a 50-day moving average of $5.57 and a 200 day moving average of $8.70.

Athira Pharma (NASDAQ:ATHA – Get Rating) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.07. Equities research analysts forecast that Athira Pharma will post -2.67 EPS for the current fiscal year.

Insider Activity

In other Athira Pharma news, insider Hans Moebius acquired 10,000 shares of the business’s stock in a transaction dated Tuesday, June 28th. The stock was bought at an average price of $2.88 per share, with a total value of $28,800.00. Following the purchase, the insider now owns 52,955 shares of the company’s stock, valued at $152,510.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Perceptive Advisors Llc purchased 270,000 shares of the stock in a transaction that occurred on Wednesday, June 29th. The stock was bought at an average cost of $2.99 per share, for a total transaction of $807,300.00. Following the acquisition, the director now directly owns 3,695,916 shares of the company’s stock, valued at approximately $11,050,788.84. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Hans Moebius purchased 10,000 shares of the stock in a transaction that occurred on Tuesday, June 28th. The shares were purchased at an average price of $2.88 per share, with a total value of $28,800.00. Following the completion of the acquisition, the insider now directly owns 52,955 shares in the company, valued at $152,510.40. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 14,767 shares of company stock valued at $39,723. Corporate insiders own 14.90% of the company’s stock.

Institutional Trading of Athira Pharma

Several institutional investors have recently bought and sold shares of the company. Wasatch Advisors Inc. boosted its holdings in shares of Athira Pharma by 38.6% during the 4th quarter. Wasatch Advisors Inc. now owns 1,242,423 shares of the company’s stock valued at $16,189,000 after acquiring an additional 346,140 shares during the last quarter. State Street Corp boosted its holdings in shares of Athira Pharma by 39.0% during the 1st quarter. State Street Corp now owns 827,574 shares of the company’s stock valued at $11,172,000 after acquiring an additional 232,280 shares during the last quarter. Woodline Partners LP purchased a new stake in shares of Athira Pharma during the 1st quarter valued at about $2,667,000. Bank of America Corp DE boosted its holdings in shares of Athira Pharma by 50.8% during the 1st quarter. Bank of America Corp DE now owns 358,742 shares of the company’s stock valued at $4,843,000 after acquiring an additional 120,876 shares during the last quarter. Finally, Walleye Capital LLC purchased a new stake in shares of Athira Pharma during the 1st quarter valued at about $1,427,000. 69.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on ATHA. Jefferies Financial Group lowered shares of Athira Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, June 22nd. Stifel Nicolaus lowered shares of Athira Pharma from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $36.00 to $5.00 in a report on Thursday, June 23rd. Mizuho began coverage on shares of Athira Pharma in a report on Wednesday, July 6th. They issued a “buy” rating and a $6.00 price objective for the company. Berenberg Bank began coverage on shares of Athira Pharma in a report on Thursday, April 21st. They issued a “buy” rating and a $33.00 price objective for the company. Finally, BTIG Research began coverage on shares of Athira Pharma in a report on Tuesday, May 10th. They issued a “buy” rating and a $33.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Athira Pharma currently has an average rating of “Hold” and an average price target of $24.00.

About Athira Pharma

(Get Rating)

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease.